Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289098 | 0.82 | GSK3B (0.51) | GSK3BCHEK1NAMPTKMT2ATDP1 | |
| SCHEMBL13288941 | 0.82 | KMT2A (0.55) | GSK3BCHEK1NAMPTKMT2ATDP1 | |
| SCHEMBL13289383 | 0.80 | GSK3B (0.52) | GSK3BCHEK1CCNE1CDK2TDP1 | |
| SCHEMBL13289102 | 0.80 | GSK3B (0.50) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL13289113 | 0.80 | GSK3B (0.51) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL13289389 | 0.80 | GSK3B (0.53) | GSK3BCHEK1CDK2NAMPTKMT2A | |
| SCHEMBL13288942 | 0.80 | GSK3B (0.53) | GSK3BCHEK1CCNE1CDK2POLB | |
| SCHEMBL13288641 | 0.79 | GSK3B (0.53) | GSK3BCHEK1CCNE1CDK2 | |
| SCHEMBL14545273 | 0.78 | GSK3B (0.52) | GSK3BCHEK1CCNE1CDK2KMT2A | |
| SCHEMBL13289387 | 0.78 | GSK3B (0.49) | GSK3BCHEK1CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |